A recent study has shown that immunosuppressive (IS) therapies for immune-mediated inflammatory diseases (IMIDs) do not increase the risk of SARS-CoV-2 or severe sequelae when controlling for other factors. In addition, tumour necrosis factor α inhibitors may lower the risk of severe infection.
Adjuvant therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib for 12 months led to long-term relapse-free survival (RFS) with no apparent long-term toxicities in patients with resected stage III melanoma with BRAF V600E or V600K mutations, according to the extended follow-up results of the phase III COMBI-AD* trial.
COVID-19 patients carry particularly high viral loads during the early stages of the disease, with millions of virus exhaled in their breath per hour, reveals a study — which indicates that breath emission could possibly contribute to airborne transmission of the virus.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.